84 results about "Peripheral nervous system" patented technology

A neurophysiological magnetic stimulation (NMS) method includes obtaining motor thresholds over one or both motor strips adhered to the patient's head or the equivalent anatomic region for treatment of non-brain, nervous system disorders. The method further includes applying magnetic stimulation coils to a therapeutic target region of the patient's brain, brainstem, spinal cord, or peripheral nervous system and applying NMS in increasing amplitudes as tolerated over the course of treatment.

The present invention relates to a novel association or combination of active ingredients useful in the prevention and repair of neuronal damage, both centrally and peripherally. In greater detail, the present invention relates to an association or combination of i) an extract of Gastrodia elata and ii) at least one ingredient selected from the group comprising or, alternatively, consisting of citicoline, L-acetylcarnitine and, preferably, at least one vitamin of group D, and / or mixtures thereof, and / or at least one vitamin of group B, and / or mixtures thereof. Furthermore, the invention also relates to the pharmaceutical compositions and / or compositions for medical devices (Regulation (EU) 2017 / 745) and / or nutraceutical and / or food compositions comprising that association and to their use in therapy, in particular in the protection of the functionality of the nervous system and in the prevention and / or treatment of central and peripheral neuropathies.

Methods of treating a nerve injury are disclosed. The methods include administering to a target site of the nerve injury a thermally stable preparation having a purified amphiphilic peptide in an aqueous biocompatible solution, being configured to self-assemble into a hydrogel, and administering to the target site a buffer having an effective amount of an ionic salt and a biological buffering agent to form the hydrogel. The methods include administering to the target site a biological material suspension in an amount effective to treat the nerve injury. The methods include administering to the target site an anti-scarring agent in an amount effective to treat the nerve injury. The target site is associated with central nervous system tissue or peripheral nervous system tissue. The nerve injury includes spinal cord injury and peripheral nerve injury.

The disclosure concerns compositions and methods for treatment of encephalopathies, including encephalopathies caused by, or associated with, and STXBP1 haploinsufficiency or mutation. Compositions and methods provided herein encompass AAV particles that encapsidate the STXBP1 transgene and allow for STXBP1 expression, including expression of STXBP1 in central and / or peripheral nervous system cells.

The present disclosure relates to a neurostimulation system, in particular for Cortical and / or Deep Brain Stimulation and / or Central Nervous System (CNS) neurostimulation / neuromodulation and / or Peripheral Nervous System (PNS) neurostimulation / neuromodulation and / or Vagus Nerve Stimulation, comprising:at least one implant unit comprising:at least one first antenna, andat least one lead having at least one electrode array with at least one electrode; andat least one wearable device comprising at least one second antenna,wherein the at least one wearable device is configured to wirelessly control and wirelessly communicate with the at least one implant unit, and wherein the at least one electrode is made of reduced graphene oxide, such as hydrothermally reduced graphene oxide.

The application provides a wireless and battery-free brain nerve stimulator and a preparation method. The brain nerve stimulator can be driven by a mobile phone loudspeaker, and a resonator designed can effectively amplify a piezoelectric signal. The brain nerve stimulator comprises two parts: a base provided with implantable nerve stimulation electrodes and a resonant cavity device connected through magnetic coupling. The design scheme of the brain nerve stimulator provides a general method for inhibiting epilepsy. The brain nerve stimulator can be extended to target brain deep layers or surface areas and peripheral nervous systems. A stimulation mode can be wirelessly transmitted and controlled. It is proved by electroencephalogram recording of free-moving mice that the wireless nerve stimulator can effectively relieve seizure events of the epileptic mice in vivo.

The present invention provides methods for targeting an agent to the peripheral nervous system of a subject. In these methods, targeting is achieved by conjugating the agent to an antibody that can transport conjugated cargo across the blood-nerve barrier. Conjugates comprising an agent conjugated to an antibody are also provided.

Techniques and systems are disclosed for a bioassay that is an in vitro mimic of peripheral nerve generation using the sensory neurons that innervate the peripheral nervous system. In some embodiments, the techniques may assist in detecting the bioactivity or potency of nerve grafts (e.g., processed, acellular human allografts) for fostering or supporting peripheral nerve regeneration. In various embodiments, techniques comprise affixing a harvested sensory neuron (e.g., a DRG) to a nerve graft segment to form a test construct; culturing the test construct in a medium; analyzing the test construct to indicate the amount of outgrowing peripheral nerve structure; and determining the potency of the nerve graft from a metric derived from the analysis. In some embodiments, techniques and materials may be used to test the effect of a varied test condition on peripheral nerve growth.

Disclosed herein are methods for treating a disease or disorder of the central or peripheral nervous system by administering to a subject in thereof an agent capable of modulating the activity or expression of bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI). Additionally, methods for screening agents capable of modulating the activity or expression of BAMBI are disclosed.

The application discloses application of a peripheral nervous system Mas-related G protein-coupled receptor D as a target point in preparation of a medicine for screening for relieving opioid tolerance. Jun The application further provides a medicine composition for regulating opioid tolerance, containing a Mas-related G protein-coupled receptor D siRNA sequence shown in SEQ ID NO. 1 or a siRNA sequence shown in SEQ ID NO. 2. The application further provides an in-situ hybridization kit for detecting expression of a Mas-related G protein-coupled receptor D gene in a dorsal root ganglion tissue of a peripheral nervous system. The application expands a new path for opioid companion diagnosis and intervention.

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

The invention discloses application of a peripheral nervous system Mas related G protein coupled receptor D as a target spot in preparing and screening a medicine for relieving opioid medicine tolerance. The invention also provides a pharmaceutical composition for regulating and controlling the tolerance of the opioid drugs. The pharmaceutical composition contains a Mas related G protein coupled receptor D siRNA sequence as shown in SEQ ID NO. 1 or a Jun siRNA sequence as shown in SEQ ID NO. 2. The invention also provides an in-situ hybridization kit for detecting the expression of the Mas related G protein coupled receptor D gene in the dorsal root ganglion tissue of the peripheral nervous system. According to the invention, a new path for accompanying diagnosis and intervention of opioid drugs is expanded.

The invention relates to selected macrocyclic compounds, and their use in the treatment or prevention of diseases and disorders. In particular, though not exclusively, the invention relates to the use of selected macrocyclic compounds in the treatment or prevention of diseases that are caused by (1) cell death due to various causes and (2) inflammation. Such diseases can affect all parts of the body, including the central and peripheral nervous systems, all organs and tissues, the muscles, the vasculature and the bones.

The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2 / Kv7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particularly in the treatment of disorders of the central nervous system (CNS), such as, for example, epilepsy and neurodegenerative disorders, and of the peripheral nervous system (PNS), such as, for example, chronic and neuropathic pain.

The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and / or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.

The present application includes compounds of Formula I and Formula II, compositions containing these compounds, and uses thereof, particularly for treating central nervous system (CNS) or peripheral nervous system (PNS) diseases, disorders, or conditions, and for promoting or improving wound healing (Formula I / II). I / II.

The present invention relates to a novel association or combination of active ingredients useful in the prevention and repair of neuronal damage, both centrally and peripherally. In greater detail, the present invention relates to an association or combination of an extract of Gastrodia elata, citicoline, L-acetylcamitine, at least one vitamin of group B and at least one vitamin of group D. Furthermore, the invention also relates to the pharmaceutical compositions and / or compositions for medical devices and / or nutraceutical and / or food compositions comprising that association and to their use in therapy, in particular in the protection of the functionality of the central and of the peripheral nervous system.

The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2 / Kv7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particularly in the treatment of disorders of the central nervous system (CNS), such as, for example, epilepsy and neurodegenerative disorders, and of the peripheral nervous system (PNS), such as, for example, chronic and neuropathic pain.

Device for the preventive blocking of neurotropic viruses in the peripheral nervous system, comprising a biochemical injection system for the localized release of a neurospecific binding molecule, a detection unit for the identification of viral particles in neuromuscular tissue, and a receptor bait structure for binding viral glycoproteins with affinity for neuronal receptors, characterized in that the device prevents retrograde axonal viral transmission without permanently impairing the conductivity of the nerve tissue.

This disclosure describes novel methods and systems enabled by machine learning models for automated, non-invasive, and in vivo quantification of mechanoreceptors. The disclosed methods and systems can be used for determining or monitoring a condition associated with peripheral nervous system disorders, such as sensory neuropathies, sensory neuronopathies, sensorimotor neuropathies, and small fiber neuropathies.

The present invention relates to novel compounds of Formula (I), wherein Z, P, Q, A, B, m, n, R1 and R2 are defined as in Formula (I); which are gamma-(γ)-aminobutyric acid type B receptor ("GABAB-R") positive allosteric modulators which are useful for the treatment or prevention of central and peripheral nervous system disorders associated with GABA dysfunction and diseases in which the GABAB receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of disorders and diseases in which GABAB-R is involved.

The disclosure relates to the field of chronic pain and the treatment thereof. The disclosure involves antisense oligonucleotides and the use thereof in pre-mRNA and mRNA modulation, in one aspect related to RNA editing using endogenous ADAR enzymes, in targeting an adenosine in a (pre-) mRNA for human Nav1.7, preferably to change from a lysine residue to an arginine residue in the protein at position 1406 (K1406R), thereby impairing the ability of the Nav1.7 protein to act as a sodium ion channel. In another aspect the disclosure relates to exon skipping wherein antisense oligonucleotides are used to induce skipping of exon 23 in the generation of human SCN9A mRNA thereby generating a shortened Nav1.7 protein with an impaired ability to act as a sodium ion channel. The disclosure relates to methods and means to alter the Nav1.7 protein in cells of the peripheral nervous system, preferably large nociceptor cells (type Aα / Aβ), to provide a treatment of chronic pain.

The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA.

Methods for diagnosing a peripheral nervous system (PNS) neuropathy comprising administering to a subject in need of treatment thereof, at least one of a translocator protein (TSPO)-targeting compound or a PSMA-targeting compound and taking an image, are disclosed.

The invention relates to a hand exoskeleton capable of changing positions and models of pressure signals to increase limb perception, which comprises a hand exoskeleton with a controller and a lining arranged in the hand exoskeleton and attached to skin, the surface of the lining is provided with a pressure sensor corresponding to the finger pulp of the sensory disorder, and is provided with a stimulation generator corresponding to the limb position more sensitive to the finger pulp of the sensory disorder, and an electromyographic signal acquisition device for receiving electromyographic signals of the limb controlled by the brain center; the controller is used for converting a pressure signal received by the pressure sensor into a stimulation signal output by the stimulation generator, receiving an electromyographic signal generated after the brain center is stimulated and then controlling exoskeleton movement. For fingers with sensory disorder caused by diseases such as central nervous system injury or peripheral nervous system injury and the like, limb perception can be increased in a transposition and model-changing stimulation mode, sensory information is fed back to the brain center through peripheral nerves, and closed-loop regulation and control with human and exoskeleton as a whole is achieved.

Disclosed herein are various bioreactor devices that mimic the mammalian joint. The bioreactor device includes a series of bioreactor chambers that contain different components of the joint, such as bone, cartilage, synovium, and ligament, and which are integrated with neural processes to better recapitulate physiological conditions, including joint pain. At least two different nutrient fluid circulation systems connect subsets of the bioreactor chambers to differentially supply nutrient fluids at concentrations optimized for the tissue that the fluid nourishes. The disclosed bioreactor devices enable interrogation of the interplay between the peripheral nervous system and joint tissues. By recording activity in sensory neurons, joint integrity as well as therapeutic efficacy can be monitored in real time.

The present disclose relates to intravertebral electrical block of spinal transmission of neural signals (at least a portion of sensory signals from the peripheral nervous system and / or at least a portion of motor signals to the peripheral nervous system). At least one intravertebral electrode can be located at a level of a spinal cord of a subject. At least one waveform generator can be coupled to the at least one intravertebral electrode and configured to generate an electrical signal that is sent to the at least one intravertebral electrode for application to the level of the spinal cord of the subject.

The present disclosure features a chemical compound (e.g., a compound or its pharma- ceutically acceptable salt, or its N-oxide) that is a positive allosteric modulator of one or more GABA-A receptors, e.g., a peripherally restricted positive allosteric modulator of one or more GABA-A receptors that selectively targets the peripheral nervous system and organs of the body and does not substantially cross the blood-brain barrier. The compound is useful, for example, for treating systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders mediated by GABA-A neuronal activity). The present disclosure also features pharmaceutical compositions containing the chemical compounds described herein, and methods of use thereof for treating systemic diseases of the body.

The invention provides application of nifurazide or a pharmaceutically acceptable derivative thereof and a pharmaceutical composition, and belongs to the technical field of biological medicines. The application comprises application of nifurazil in preparation of drugs for reducing food intake and / or inhibiting appetite. The nifurazil does not depend on blood sugar regulation and intestines and stomach, and does not cause side effects of nausea and vomiting; the action target of the nifurazil is not located in the peripheral nervous system but acts on the central nervous system, and the nifurazil can be used for remarkably reducing the intake of common food and high-fat food of mice and inhibiting the appetite of the mice in a mode of activating Glp1-r, so that the weight of the obese mice is remarkably reduced. Therefore, the nifurazil has the potential of treating the obesity and can be applied to preparation of the medicine for treating the obesity.

Described herein are compositions that comprise Bumetanide Dibenzylamide for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, the present disclosure relates to methods and compositions for treating neurological disorders by administering agents that disrupt hypersynchronized neuronal activity without diminishing neuronal excitability. These compositions are useful for seizure disorders, epilepsy, and related indications.